Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232174 | 0.84 | LPAR1 (0.62) | LPAR1LPAR3ENPP2 | |
| SCHEMBL30633511 | 0.84 | LPAR1 (0.62) | LPAR1LPAR3ENPP2 | |
| SCHEMBL17320970 | 0.84 | LPAR1 (0.62) | LPAR1LPAR3ENPP2 | |
| SCHEMBL29651480 | 0.84 | LPAR1 (0.62) | LPAR1LPAR3ENPP2 | |
| SCHEMBL17482404 | 0.78 | LPAR1 (0.55) | LPAR1LPAR3ENPP2 | |
| SCHEMBL29372509 | 0.78 | LPAR1 (0.55) | LPAR1LPAR3ENPP2 | |
| SCHEMBL9905965 | 0.75 | ALDH1A1 (0.55) | — | |
| SCHEMBL29961411 | 0.75 | ENPP2 (0.57) | LPAR1LPAR3ENPP2 | |
| SCHEMBL29651433 | 0.75 | LPAR1 (0.52) | LPAR1LPAR3 | |
| SCHEMBL9905963 | 0.72 | ADORA3 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10413559-B2 | Method for treating demyelinating disease | OCHANOMIZU UNIVERSITY (JP) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10413559-B2 | Method for treating demyelinating disease | PMP22, MAG, SGMS1 | LPAR1 15/4885LPAR3 13/4885ENPP2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.